New Randomized Controlled Trial Confirms Low-Dose Q-actin™ Supports Joint Comfort and Function

Carson City, Nevada – October 8, 2025 – IminoTech today announced results from a new randomized, double-blind, placebo-controlled clinical trial showing that Q-actin™ (cucumber extract standardized to idoBR1) at 20 mg/day significantly improved joint comfort and function in adults with mild–moderate joint pain over 60 days. The study, published in Cureus, an open-access, peer-reviewed medical journal, adds to a growing body of evidence for Q-actin’s efficacy at a remarkably small daily serving.

Study Design

Eighty adults with mild–moderate joint pain consumed 20 mg/day of Q-actin or placebo for 60 days. Assessments were conducted at Days 15, 30, and 60 using WOMAC, Lequesne Functional Index, Brief Pain Inventory (BPI), and Pain Disability Index (PDI).

Key Findings

Significant improvements with Q-actin emerged by Day 30 and strengthened throughout the study. By Day 60, Q-actin participants experienced a 31.79% decrease in WOMAC scores (less pain and stiffness; better function), a 32.39% reduction on the Pain Disability Index (PDI) (less interference with work, sleep, mood, and daily activities), and a 10.07% improvement on the Lequesne Functional Index (measurable gains in mobility and functional capacity). Percent changes are within-group from baseline to Day 60.

“These results not only confirm Q-actin’s benefits, they extend them beyond previous osteoarthritis studies to adults with mild to moderate joint pain,” said Shil Kothari, Chief Executive Officer of IminoTech. “Consistent outcomes with a tiny 20 mg daily dose show Q-actin delivers reliable, everyday joint health benefits that consumers can feel.”

Why It Matters for Product Developers

At just 20 mg/day, Q-actin fits easily into capsules, gummies, or stick packs while delivering meaningful benefits as early as Day 30. Because this study enrolled adults with mild–moderate joint pain, the findings translate beyond OA clinics to everyday joint-comfort positioning. And with a plant-derived extract standardized to a defined bioactive (idoBR1), brands have a clean, credible story that’s easy to formulate and communicate.

Publication

Cureus (2025): “Efficacy of a Cucumber Extract (Q-actin™) in Adults with Mild–Moderate Joint Pain: A Randomized, Double-Blind, Placebo-Controlled Trial.” PubMed ID: 41040766.

About Q-actin

Q-actin™ is a clinically studied cucumber extract standardized to idoBR1, developed to support joint comfort, stiffness, and function at a clinically effective 20 mg daily dose. Multiple randomized trials, including a comparison study with glucosamine-chondroitin and placebo-controlled design, have demonstrated significant improvements on validated joint-health scales.

Q-actin reduces TNF-α–driven inflammation and dampens cartilage-degrading enzyme activity (e.g., MMP-3, select glycosidases), offering a novel, multi-pathway approach to joint comfort and function.